Fulgent Genetics EBITDA Margin 2015-2024 | FLGT
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Fulgent Genetics (FLGT) over the last 10 years. The current EBITDA margin for Fulgent Genetics as of December 31, 2024 is .
| Fulgent Genetics EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-09-30 | $0.28B | $-0.07B | -24.46% |
| 2024-06-30 | $0.29B | $-0.05B | -17.53% |
| 2024-03-31 | $0.29B | $-0.05B | -17.71% |
| 2023-12-31 | $0.29B | $-0.05B | -18.28% |
| 2023-09-30 | $0.29B | $-0.05B | -18.47% |
| 2023-06-30 | $0.31B | $-0.05B | -15.26% |
| 2023-03-31 | $0.37B | $-0.01B | -3.01% |
| 2022-12-31 | $0.62B | $0.22B | 34.89% |
| 2022-09-30 | $0.80B | $0.40B | 49.56% |
| 2022-06-30 | $0.93B | $0.55B | 59.68% |
| 2022-03-31 | $0.95B | $0.63B | 66.35% |
| 2021-12-31 | $0.99B | $0.69B | 69.89% |
| 2021-09-30 | $1.04B | $0.77B | 73.94% |
| 2021-06-30 | $0.91B | $0.67B | 73.08% |
| 2021-03-31 | $0.77B | $0.57B | 73.09% |
| 2020-12-31 | $0.42B | $0.29B | 69.67% |
| 2020-09-30 | $0.14B | $0.07B | 48.89% |
| 2020-06-30 | $0.04B | $0.00B | 9.30% |
| 2020-03-31 | $0.03B | $0.00B | 5.88% |
| 2019-12-31 | $0.03B | $0.00B | 6.45% |
| 2019-09-30 | $0.03B | $0.00B | 6.90% |
| 2019-06-30 | $0.03B | 0 | 0.00% |
| 2019-03-31 | $0.02B | $-0.00B | -4.55% |
| 2018-12-31 | $0.02B | $-0.00B | -9.09% |
| 2018-09-30 | $0.02B | $-0.00B | -20.00% |
| 2018-06-30 | $0.02B | $-0.01B | -26.32% |
| 2018-03-31 | $0.02B | $-0.01B | -26.32% |
| 2017-12-31 | $0.02B | $-0.00B | -10.53% |
| 2017-09-30 | $0.02B | $0.00B | 9.52% |
| 2017-06-30 | $0.02B | $0.00B | 14.29% |
| 2017-03-31 | $0.02B | $0.00B | 20.00% |
| 2016-12-31 | $0.02B | $0.00B | 16.67% |
| 2016-06-30 | $0.01B | $0.00B | 20.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.512B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $36.709B | 54.09 |
| Hims & Hers Health (HIMS) | United States | $11.210B | 183.25 |
| Tempus AI (TEM) | United States | $10.954B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $5.532B | 107.78 |
| IRhythm Technologies (IRTC) | United States | $3.734B | 0.00 |
| Privia Health (PRVA) | United States | $2.941B | 245.10 |
| Enovis (ENOV) | United States | $2.475B | 16.49 |
| Clover Health Investments (CLOV) | United States | $2.095B | 0.00 |
| Azenta (AZTA) | United States | $2.083B | 96.98 |
| Omnicell (OMCL) | United States | $1.845B | 40.23 |
| Schrodinger (SDGR) | United States | $1.580B | 0.00 |
| Phreesia (PHR) | United States | $1.577B | 0.00 |
| 10x Genomics (TXG) | United States | $1.381B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.859B | 0.00 |
| Standard BioTools (LAB) | United States | $0.495B | 0.00 |
| Talkspace (TALK) | United States | $0.481B | 285.00 |
| TruBridge (TBRG) | United States | $0.423B | 123.26 |
| Nyxoah SA (NYXH) | Belgium | $0.353B | 0.00 |
| Pulmonx (LUNG) | United States | $0.352B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.305B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.257B | 0.00 |
| American Well (AMWL) | United States | $0.174B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.097B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.085B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.075B | 0.00 |
| 111 (YI) | China | $0.072B | 0.00 |
| CareCloud (CCLD) | United States | $0.054B | 0.00 |
| HeartBeam (BEAT) | United States | $0.054B | 0.00 |
| Outset Medical (OM) | United States | $0.044B | 0.00 |
| Zepp Health (ZEPP) | China | $0.042B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.038B | 0.00 |
| Zhongchao (ZCMD) | China | $0.034B | 0.00 |
| Movano (MOVE) | United States | $0.032B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.015B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.015B | 0.00 |
| Precipio (PRPO) | United States | $0.014B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.013B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Syra Health (SYRA) | United States | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |